BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Güertler L, Ironside JW. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev 2016;30:35-48. [PMID: 26381318 DOI: 10.1016/j.blre.2015.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang F, Pritzkow S, Soto C. PMCA for ultrasensitive detection of prions and to study disease biology. Cell Tissue Res 2022;:1-15. [PMID: 36567368 DOI: 10.1007/s00441-022-03727-5] [Reference Citation Analysis]
2 Santos P, Gomes ATPC, Lourenço LMO, Faustino MAF, Neves MGPMS, Almeida A. Anti-Viral Photodynamic Inactivation of T4-like Bacteriophage as a Mammalian Virus Model in Blood. IJMS 2022;23:11548. [DOI: 10.3390/ijms231911548] [Reference Citation Analysis]
3 Di Minno G, Castaman G, De Cristofaro R, Brunetti-Pierri N, Pastore L, Castaldo G, Trama U, Di Minno M. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. Blood Rev 2022;:101011. [PMID: 36031462 DOI: 10.1016/j.blre.2022.101011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Di Minno A, Gelzo M, Caterino M, Costanzo M, Ruoppolo M, Castaldo G. Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine. Int J Mol Sci 2022;23:5213. [PMID: 35563604 DOI: 10.3390/ijms23095213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Fachini RM, Fontão-Wendel R, Achkar R, Scuracchio P, Brito M, Amaral M, Wendel S. The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital. Pathogens 2021;10:1499. [PMID: 34832654 DOI: 10.3390/pathogens10111499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Windyga J, Timofeeva M, Stasyshyn O, Mamonov V, Lamas Castellanos JL, Lissitchkov T, Chojnowski K, Chapman M, Pavlova BG, Tangada S. Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B. Clin Appl Thromb Hemost 2020;26:1076029620946839. [PMID: 32816519 DOI: 10.1177/1076029620946839] [Reference Citation Analysis]
7 Peyvandi F, Garagiola I, Mannucci PM. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Rev 2021;49:100828. [PMID: 33810898 DOI: 10.1016/j.blre.2021.100828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Di Minno A, Gelzo M, Stornaiuolo M, Ruoppolo M, Castaldo G. The evolving landscape of untargeted metabolomics. Nutr Metab Cardiovasc Dis 2021;31:1645-52. [PMID: 33895079 DOI: 10.1016/j.numecd.2021.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
9 Allah HMA, Abdo E, Elamin EAE, Abdelghani S, Eltayeb LB. Molecular Screening for Transfusion Transmissible P. falciparum in Asymptomatic Blood Donors in the Non-endemic Region. J Biochem Technol 2021;12:6-10. [DOI: 10.51847/d8p0p9b063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Coulibaly M, Maiga B, Samaké D, Diawara M, Traoré M, Sagara V, Traoré B, Guindo O, Dolo A. Assessment of Rapid Diagnostic Tests Algorithms in Transfusion Medicine Setting. ABC 2021;11:52-63. [DOI: 10.4236/abc.2021.111005] [Reference Citation Analysis]
11 Chabay P, Lens D, Hassan R, Rodríguez Pinilla SM, Valvert Gamboa F, Rivera I, Huamán Garaicoa F, Ranuncolo SM, Barrionuevo C, Morales Sánchez A, Scholl V, De Matteo E, Preciado MV, Fuentes-Pananá EM. Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated Malignancies. A Literature-Based Study by the RIAL-CYTED. Cancers (Basel) 2020;12:E2166. [PMID: 32759793 DOI: 10.3390/cancers12082166] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Nafari AH, Ayadi A, Noormohamadi Z, Sakhaee F, Vaziri F, Siadat SD, Fateh A. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms. Infection, Genetics and Evolution 2020;79:104144. [DOI: 10.1016/j.meegid.2019.104144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Fong IW. Blood Transfusion-Associated Infections in the Twenty-First Century: New Challenges. Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_8] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
14 Kadhim KAR, Al-Lami FH, Baldawi KH. Epidemiological Profile of Hemophilia in Baghdad-Iraq. Inquiry 2019;56:46958019845280. [PMID: 31081421 DOI: 10.1177/0046958019845280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Sousa V, Gomes ATPC, Freitas A, Faustino MAF, Neves MGPMS, Almeida A. Photodynamic Inactivation of Candida albicans in Blood Plasma and Whole Blood. Antibiotics (Basel) 2019;8:E221. [PMID: 31766190 DOI: 10.3390/antibiotics8040221] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
16 Ayadi A, Nafari AH, Sakhaee F, Rajabi K, Ghaderi Y, Rahimi Jamnani F, Vaziri F, Siadat SD, Fateh A. Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection? Hepatol Res 2019;49:605-16. [PMID: 30821879 DOI: 10.1111/hepr.13325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Lyon A, Mays CE, Borriello F, Telling GC, Soto C, Pritzkow S. Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics. Sci Rep 2019;9:4847. [PMID: 30890734 DOI: 10.1038/s41598-019-41055-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Kiely P. Decision Systems. Blood Safety 2019. [DOI: 10.1007/978-3-319-94436-4_5] [Reference Citation Analysis]
19 Deb PK, Al-attraqchi OHA, Stanslas J, Al-aboudi A, Al-attraqchi N, Tekade RK. Biotechnology-Based Pharmaceutical Products. Biomaterials and Bionanotechnology 2019. [DOI: 10.1016/b978-0-12-814427-5.00005-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019;133:415-24. [PMID: 30559262 DOI: 10.1182/blood-2018-06-820738] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
21 Thornburg CD. How I approach: Previously untreated patients with severe congenital hemophilia A. Pediatr Blood Cancer 2018;65:e27466. [DOI: 10.1002/pbc.27466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Di Minno A, Spadarella G, Nardone A, Mormile M, Ventre I, Morfini M, Di Minno G. Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. Blood Rev 2019;33:106-16. [PMID: 30146094 DOI: 10.1016/j.blre.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
23 Xiong Y, McQuistan TJ, Stanek JW, Summerton JE, Mata JE, Squier TC. Detection of unique Ebola virus oligonucleotides using fluorescently-labeled phosphorodiamidate morpholino oligonucleotide probe pairs. Anal Biochem 2018;557:84-90. [PMID: 30030994 DOI: 10.1016/j.ab.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
24 Fred HL, Thangam M, Aisenberg GM. Pathogens transmitted in red blood cell transfusions: An up-to-date table. Proc (Bayl Univ Med Cent) 2018;31:307-9. [PMID: 29904294 DOI: 10.1080/08998280.2018.1459397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Bijvand Y, Aghasadeghi MR, Sakhaee F, Pakzad P, Vaziri F, Saraji AA, Jamnani FR, Siadat SD, Fateh A. First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia. Sci Rep 2018;8:5036. [PMID: 29568043 DOI: 10.1038/s41598-018-23490-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
26 Mannucci PM. Viral safety of coagulation factor concentrates: memoirs from an insider. J Thromb Haemost 2018;16:630-3. [PMID: 29383815 DOI: 10.1111/jth.13963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Poon M, Di Minno G, Zotz R, d’Oiron R. Glanzmann’s thrombasthenia: strategies for identification and management. Expert Opinion on Orphan Drugs 2017;5:641-53. [DOI: 10.1080/21678707.2017.1341306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Di Minno G, Navarro D, Perno CF, Canaro M, Gürtler L, Ironside JW, Eichler H, Tiede A. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol 2017;96:1253-70. [PMID: 28624906 DOI: 10.1007/s00277-017-3028-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
29 Kiely P, Gambhir M, Cheng AC, McQuilten ZK, Seed CR, Wood EM. Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk. Transfus Med Rev 2017;31:154-64. [PMID: 28545882 DOI: 10.1016/j.tmrv.2017.05.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
30 Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017;15:512-21. [PMID: 28488960 DOI: 10.2450/2017.0344-16] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
31 Lyseng-williamson KA. Recombinant von Willebrand factor (vonicog alfa) in von Willebrand disease: a guide to its use. Drugs Ther Perspect 2016;32:456-462. [DOI: 10.1007/s40267-016-0350-1] [Reference Citation Analysis]
32 Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev 2016;30:92-9. [PMID: 26968829 DOI: 10.1016/j.tmrv.2016.01.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]